WO2008039267A3 - Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions - Google Patents
Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions Download PDFInfo
- Publication number
- WO2008039267A3 WO2008039267A3 PCT/US2007/016529 US2007016529W WO2008039267A3 WO 2008039267 A3 WO2008039267 A3 WO 2008039267A3 US 2007016529 W US2007016529 W US 2007016529W WO 2008039267 A3 WO2008039267 A3 WO 2008039267A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- influenza virus
- peptide
- nucleic acid
- immune responses
- cellular immune
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002658559A CA2658559A1 (en) | 2006-07-21 | 2007-07-23 | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions |
AU2007300663A AU2007300663A1 (en) | 2006-07-21 | 2007-07-23 | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions |
EP07861332.0A EP2069376A4 (en) | 2006-07-21 | 2007-07-23 | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83211206P | 2006-07-21 | 2006-07-21 | |
US60/832,112 | 2006-07-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008039267A2 WO2008039267A2 (en) | 2008-04-03 |
WO2008039267A3 true WO2008039267A3 (en) | 2008-12-31 |
Family
ID=39230737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/016529 WO2008039267A2 (en) | 2006-07-21 | 2007-07-23 | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2069376A4 (en) |
AU (1) | AU2007300663A1 (en) |
CA (1) | CA2658559A1 (en) |
WO (1) | WO2008039267A2 (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009053535A2 (en) * | 2007-10-26 | 2009-04-30 | Glykos Finland Oy | Peptide vaccine for influenza virus |
HUE029921T2 (en) | 2007-06-25 | 2017-04-28 | The Administrators Of The Tulane Educational Fund | Influenza inhibiting compositions and methods |
US8747861B2 (en) | 2007-08-02 | 2014-06-10 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope influenza vaccines |
FI20080333A0 (en) * | 2008-05-02 | 2008-05-02 | Glykos Finland Oy | Influenza virus nucleic acids and peptides |
CN102281896A (en) * | 2008-11-19 | 2011-12-14 | 阿维-梅克斯实验室公司 | Recombinant inactivated viral vector vaccine |
US8282938B2 (en) * | 2008-11-28 | 2012-10-09 | National Institute Of Infectious Diseases | Immunogenic compositions comprising liposomes and an influenza PB2 CTL epitope obtained from the highly pathogenic H5N1 strain |
CA2750922A1 (en) * | 2009-01-28 | 2010-08-05 | Antigen Express, Inc. | Li-key hybrid peptides that modulate the immune response to influenza |
JP5792630B2 (en) | 2009-01-28 | 2015-10-14 | エピミューン,インコーポレイティド | PAN-DR binding polypeptides and uses thereof |
CN101792745B (en) | 2009-02-04 | 2014-09-17 | 中国科学院生物物理研究所 | Expression and purification of influenza virus polymerase PA N-terminal polypeptide and crystal structure thereof |
CN101565455B (en) * | 2009-05-25 | 2012-03-14 | 中国科学院微生物研究所 | CTL epitope polypeptides of bird flu H5N1 virus and applications thereof |
US8926982B2 (en) * | 2009-06-01 | 2015-01-06 | Xuguang Li | Reagents and methods for detecting influenza virus proteins |
US8865182B2 (en) | 2009-07-31 | 2014-10-21 | Paxvax, Inc. | Adenoviral-based vectors |
CA2775720A1 (en) * | 2009-09-30 | 2011-04-07 | Saint Louis University | Peptides for inducing heterosubtypic influenza t cell responses |
CN102153621B (en) * | 2010-02-12 | 2014-07-02 | 广东省疾病预防控制中心 | B-cell epitope of NA-protein for new influenza A (H1N1) and application thereof |
WO2011101031A1 (en) * | 2010-02-19 | 2011-08-25 | Université de Liège | A polynucleotide for use in treatment of influenza a virus induced diseases, encoding modified mx protein, said modified mx protein, and a transgenic animal expressing gene encoding modified mx protein |
WO2011138032A2 (en) * | 2010-05-05 | 2011-11-10 | Artemev, Timur | Universal influenza vaccines and methods for their generation |
CA2810928A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
CN103517713A (en) | 2011-02-22 | 2014-01-15 | 彼昂德瓦克斯医药有限公司 | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
US20140302124A1 (en) * | 2011-10-19 | 2014-10-09 | Immunotape, Inc. | Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION |
CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
WO2013093514A2 (en) * | 2011-12-23 | 2013-06-27 | Retroscreen Virology Ltd | Vaccines - peptides |
CN104321333A (en) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | Solid forms of a thiophosphoramidate nucleotide prodrug |
WO2013142157A1 (en) | 2012-03-22 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
CN109045294A (en) * | 2013-01-10 | 2018-12-21 | 思齐乐 | Influenza virus immunization Immunogenic Compositions and its application |
CN103333224B (en) * | 2013-05-10 | 2015-03-25 | 中国农业科学院哈尔滨兽医研究所 | Avian influenza virus NS1 protein B cell epitope polypeptide and applications thereof |
JP6525214B2 (en) * | 2014-06-03 | 2019-06-05 | 国立研究開発法人農業・食品産業技術総合研究機構 | Antibody or antibody fragment containing the variable region thereof, antigenic polypeptide, and use thereof |
CA3048448A1 (en) | 2016-12-28 | 2018-07-05 | Invvax, Inc. | Influenza vaccines |
CN106589105B (en) * | 2017-01-23 | 2020-09-15 | 中国医科大学 | HLA-A2-restricted ECM 1-specific CTL epitope peptide and application thereof |
WO2019046901A1 (en) * | 2017-09-08 | 2019-03-14 | The University Of Melbourne | Methods and compositions for preventing influenza infection |
JP7320601B2 (en) * | 2018-09-11 | 2023-08-03 | 上▲海▼市公共▲衛▼生▲臨▼床中心 | Broad-spectrum anti-influenza vaccine immunogen and its use |
JP2023530134A (en) * | 2020-06-19 | 2023-07-13 | インターベット インターナショナル ベー. フェー. | A swine influenza A virus vaccine comprising a nucleic acid construct comprising first, second and third nucleic acid sequences encoding separate neuraminidase antigens of the virus |
EP4168428A1 (en) * | 2020-06-19 | 2023-04-26 | Intervet International B.V. | Swine influenza a virus vaccine comprising a nucleic acid construct encoding antigens of specific virus lineages |
WO2022032274A1 (en) * | 2020-08-02 | 2022-02-10 | Richard Ascione | Vaccine compositions for influenza viruses and methods of use |
CN116234813A (en) * | 2020-08-25 | 2023-06-06 | 基因泰克公司 | Assays and reagents for characterizing MHCI peptide binding |
CN116410271A (en) * | 2023-03-13 | 2023-07-11 | 华南农业大学 | H5N1 subtype AIV MHC B1 restricted T cell epitope peptide and application thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7572620B2 (en) * | 2005-01-11 | 2009-08-11 | Wisconsin Alumni Research Foundation | H3 equine influenza A virus |
-
2007
- 2007-07-23 CA CA002658559A patent/CA2658559A1/en not_active Abandoned
- 2007-07-23 WO PCT/US2007/016529 patent/WO2008039267A2/en active Application Filing
- 2007-07-23 EP EP07861332.0A patent/EP2069376A4/en not_active Withdrawn
- 2007-07-23 AU AU2007300663A patent/AU2007300663A1/en not_active Abandoned
Non-Patent Citations (4)
Title |
---|
DATABASE GENBANK [online] 4 September 1998 (1998-09-04), XP008103447, Database accession no. (AF036356) * |
HOELSCHER M.A. ET AL.: "Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice", THE LANCET, vol. 367, no. 9509, 11 February 2006 (2006-02-11), pages 475 - 481, XP025093947 * |
MARIA GRAZIA CUSI, HUMAN VACCINES, vol. 2, no. 1, January 2006 (2006-01-01) - February 2006 (2006-02-01), pages 1 - 7, XP008103504 * |
See also references of EP2069376A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP2069376A2 (en) | 2009-06-17 |
CA2658559A1 (en) | 2008-04-03 |
EP2069376A4 (en) | 2013-10-16 |
AU2007300663A1 (en) | 2008-04-03 |
WO2008039267A2 (en) | 2008-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008039267A3 (en) | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions | |
WO2005089164A3 (en) | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions | |
WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
EP1246644A4 (en) | Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions | |
EP1200109A4 (en) | Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions | |
WO2010060051A3 (en) | Systems biology approach predicts the immunogenicity of vaccines | |
EA201071087A1 (en) | MONOCLONAL ANTIBODIES, CAPABLE OF INTERACTIONING WITH A MANY SUBTIPS OF THE INFLUENZA VIRUS | |
WO2007095320A3 (en) | Hpv antigens, vaccine compositions, and related methods | |
EP3266464A3 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
WO2010010466A3 (en) | Neutralizing anti-influenza a virus antibodies and uses thereof | |
WO2007120673A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
EA201270063A1 (en) | PCB RECOMBINANT ANTIGENS | |
EA201070794A1 (en) | Recombinant antigens RSV | |
WO2009026397A3 (en) | Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods | |
WO2009072767A3 (en) | A powerful vaccine composition comprising a lipopeptide and poly i:c as an adjuvant | |
WO2008157419A3 (en) | Immunogenic peptides of influenza virus | |
WO2007024941A3 (en) | Polyvalent vaccine | |
BR112014004860A2 (en) | influenza virus antibody compositions | |
ATE494906T1 (en) | CELL-DERIVED VIRAL VACCINES WITH LOW AMOUNTS OF RESIDUAL CELL DNA | |
WO2004075829A3 (en) | Adjuvanted influenza vaccine | |
WO2008083239A3 (en) | Compositions and methods for stimulating an immune response | |
WO2010019262A3 (en) | Polyvalent vaccine | |
EA200970586A1 (en) | HUMAN CYTOMEGAL VIRUS ANTIBODIES (HCMV) | |
WO2009009759A3 (en) | Yersinia pestis antigens, vaccine compositions, and related methods | |
WO2008134643A3 (en) | Trypanosoma antigens, vaccine compositions, and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07861332 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2658559 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007300663 Country of ref document: AU |
|
REEP | Request for entry into the european phase |
Ref document number: 2007861332 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007861332 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
ENP | Entry into the national phase |
Ref document number: 2007300663 Country of ref document: AU Date of ref document: 20070723 Kind code of ref document: A |